Advanced Enzyme Technologies Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Advanced Enzyme Technologies reported Q1 FY27 revenue of INR 1,898 million, up 2% YoY but down 7% sequentially, with management attributing the softness to an incremental sales reversal of INR 100 million related to revenue recognition timing. EBITDA declined 10% YoY to INR 510 million with margin at 27%, which management said was due to lower top-line realization, elevated power and fuel costs, and a temporary shift in sales mix. The company also announced a buyback of INR 697 million and the acquisition of the remaining 4.28% stake in JC Biotech, making it a wholly-owned subsidiary.
Advanced Enzyme Technologies reported its highest-ever quarterly and annual revenue for FY26, with Q4 revenue of INR 2,034 million, up 22% YoY, and full-year revenue of INR 7,458 million, up 17%. EBITDA margin remained at 31% for both the quarter and the year, while PAT grew 69% YoY in Q4 and 30% for the full year. Management attributed the growth to strength across Human Healthcare, Animal Healthcare, Bioprocessing and Specialized Manufacturing segments, and flagged input cost inflation and U.S. market uncertainty as ongoing considerations for the coming year.